Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 8/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 2/20 | 0.32 |
| ▸ | LPL | P06858 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2559591 | 0.85 | ALDH1A1 (0.41) | ENPP2MGLL | |
| SCHEMBL29825639 | 0.81 | KDM1A (0.46) | ENPP2LPLLIPG | |
| SCHEMBL8351 | 0.81 | KDM1A (0.46) | ENPP2LPLLIPG | |
| SCHEMBL3587911 | 0.81 | AAK1 (0.38) | ENPP2AAK1MGLL | |
| SCHEMBL6890847 | 0.79 | ENPP2 (0.40) | ENPP2LPLLIPG | |
| SCHEMBL177284 | 0.79 | MAPT (0.40) | ENPP2LPLLIPG | |
| SCHEMBL12126095 | 0.78 | ENPP2 (0.35) | ENPP2HIF1ALPLLIPG | |
| SCHEMBL18997072 | 0.78 | MEN1 (0.43) | AAK1 | |
| SCHEMBL23363515 | 0.77 | ENPP2 (0.43) | ENPP2HIF1ALPLLIPG | |
| SCHEMBL1823994 | 0.77 | KDR (0.44) | ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004459-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2128136-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004459-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | XDH, NUDT1, PNPO | ENPP2 487/4885AAK1 1888/4885DGAT1 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.